Wed, Aug 20, 2014, 11:52 AM EDT - U.S. Markets close in 4 hrs 8 mins

Recent

% | $
Quotes you view appear here for quick access.

TaxuCardium Pharmaceuticals Group Inc. Message Board

ada95_lovelace 6 posts  |  Last Activity: Aug 12, 2014 3:26 PM Member since: Aug 5, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    The horrors of the tape…LOL …

    by trademaker_va Aug 12, 2014 3:09 PM
    ada95_lovelace ada95_lovelace Aug 12, 2014 3:26 PM Flag

    Have another Merlot while I am on my second Caipirinha ;)

    It's all good!

  • ada95_lovelace ada95_lovelace Aug 12, 2014 9:13 AM Flag

    Not IF but WHEN!!!!!

    Told ya

  • ada95_lovelace ada95_lovelace Aug 12, 2014 7:14 AM Flag

    MDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay

    The Centers for Medicare & Medicaid Services issues a preliminary decision to cover the cost of the test

    IRVINE, CA, and HERSTAL, BELGIUM - August 12, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the U.S. Food and Drug Administration's (FDA) has approved Exact Sciences' Cologuard® stool-DNA-based, non-invasive colorectal cancer screening test. The test incorporates one of MDxHealth's epigenetic biomarkers, which was licensed Upon product launch, anticipated before the end of 2014, MDxHealth expects to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.

  • Check out Mdx Health (MDXH) at current price. Mdx Health methylation specific PCR (MSP) technology was licensed to Exact Sciences in July 2010.
    MDXH has already received milestone payments and will do so upon approval and once commercialisation starts. So it's a win/win for both these companies.

  • ada95_lovelace by ada95_lovelace Jun 30, 2014 9:09 AM Flag

    Daily Iron Ore Mine Closings in China Make Citi Bullish
    By Jasmine Ng Jun 30, 2014 1:47 PM GMT+0200

    Rio Tinto CEO Says $80 a Ton for Iron Ore `Too Low'

    Iron ore prices, which completed a second straight quarterly loss today, will rebound as the daily closure of mines supplying high-cost output in China boosts demand for seaborne shipments, according to Citigroup Inc.

    Local suppliers in Asia’s largest economy are cutting production even as mills increase steel output on improved margins, according to analyst Ivan Szpakowski. An iron ore mine in China is being shuttered every day, with closures seen in all main producing regions, he said in an interview from Shanghai.

    Producers in China, the world’s largest user, face a rising challenge of lower-cost supplies from BHP Billiton Ltd. (BHP), Fortescue Metals Group Ltd. (FMG) and Vale SA (VALE5) after the biggest miners in Australia and Brazil expanded output and spurred a global glut. While benchmark prices in China posted the biggest three-month loss since 2012, they rose 2.2 percent in June, the first monthly advance since November.

    “We’re one of the most bullish people in the market,” said Szpakowski, reiterating a forecast for prices to average $100 a ton in the fourth quarter and $104 this year. “Imported ore is much cheaper than domestic ore, so the shift in buying has moved to imported ore. That’s supporting imported prices.”

    Ore with 62 percent iron content delivered to Tianjin fell 1.2 percent to $93.80 a dry ton today, according to data from The Steel Index Ltd. The commodity lost 20 percent this quarter, following a 13 percent decline between January and March. Prices advanced 3 percent last week, the most since the period ended August 16.
    Mine Closures

    “Supply in China ha

  • Statistically significant improvement in key parameters of heart function, including left ventricular ejection fraction and cardiac output

    June 10, 2014 — Mast Therapeutics Inc. announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of heart function, including left ventricular ejection fraction and end-systolic volume, stroke volume and cardiac output. Notably, a single two-hour infusion of MST-188 resulted in improvements that were significant immediately (at the end of MST-188 administration) and remained significant at one week (and, in some cases, at two weeks) after MST-188 administration.

    Hani N. Sabbah, Ph.D., professor of medicine & director of cardiovascular research at Henry Ford Health System in Detroit, said: "These data clearly show that MST-188 improves left ventricular ejection fraction and end-systolic volume, both of which are important indicators of long-term mortality and morbidity in chronic heart failure, with some effects lasting up to two weeks post-infusion. The durability of response is very encouraging and merits clinical investigation."

    Santosh Vetticaden, M.D., Ph.D., chief medical officer of Mast Therapeutics, said: "Heart failure is an area of significant unmet medical need that accounts for over 1 million hospitalizations every year in the U.S. alone. Although there have been modest improvements in treatment, heart failure remains associated with significant mortality and high rates of hospital admission and readmission. We look forward to discussing these results with heart failure experts and potential partners and mapping our clinical development strategy in this exciting new indication."

    The company has submitted data from this clinical study for presentation at an upcoming medical conference and will provide an update on its plans for MST-188 in heart failure later in 2014.

    The objective of the study was to dete

CRXM
0.4798-0.0002(-0.04%)Aug 20 10:26 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.